Clinical Effectiveness and Safety of Dipeptidyl Peptidase-1 Inhibitors in Non-Cystic Fibrosis Bronchiectasis with Recurrent Exacerbations: A Systematic Review and Meta-Analysis

Non-cystic fibrosis bronchiectasis is a chronic inflammatory airway disease characterized by impaired mucus clearance, recurrent pulmonary exacerbations and neutrophil-dominant airway injury. Dipeptidyl peptidase-1 (DPP-1) inhibition suppresses activation of neutrophil serine proteases and is a plausible targeted anti-inflammatory strategy. This review evaluates DPP-1 inhibitors as a class, rather than brensocatib alone, in adults with bronchiectasis and recurrent exacerbations.